IPP Bureau
Sun Pharmaceutical Q3FY21 net profit at Rs. 1852.48 Cr
By IPP Bureau - February 01, 2021
The company has reported total income of Rs.25699.68 crores during the 9 months period ended December 31, 2020.
CIPLA Q3 FY21 PAT up to Rs. 748.15 Cr
By IPP Bureau - February 01, 2021
The company has reported total income of Rs.14759 crores during the 9 months period ended December 31, 2020.
Laurus Q3 FY21 revenue up 76%; PAT grows 274%
By IPP Bureau - January 29, 2021
The company has concluded our acquisition of Richcore Lifesciences on 20th Jan 2021.
Lonza reports 12% sales growth in 2020
By IPP Bureau - January 28, 2021
Lonza maintained business continuity during the COVID-19 pandemic with minimal impacts to operations and supply throughout 2020.
Aurobindo Pharma gets approval for 3 products under PLI Scheme: ICICI Securities
By IPP Bureau - January 26, 2021
Post approval under the PLI scheme, Aurobindo will become a very large player in anti-biotic space.
Slow recovery in biosimilars for Biocon: ICICI Securities
By IPP Bureau - January 26, 2021
Dr Christiane Hamacher, has stepped down as the MD of Biocon Biologics and will be succeeded by Dr Arun Chandavarkar.
Biocon Q3 FY21 revenue up 7% at Rs. 1,879 Cr
By IPP Bureau - January 23, 2021
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Syngene Q3 revenue up 13% to Rs. 585 Cr
By IPP Bureau - January 22, 2021
EBITDA and PAT for the quarter were both up 11% to Rs. 193 crores and Rs. 102 crores respectively.
Shilpa Medicare CFO resigns
By IPP Bureau - January 20, 2021
The commercial production in the SML was started in November 1989.
Zydus eyes $6 bn market with strong COVID-19 portfolio
By IPP Bureau - January 18, 2021
With a mix of vaccines targeting different stages of COVID-19, the company is eyeing huge market potential
Dr. Reddy’s gets approval for Sputnik V Phase 3 trial
By IPP Bureau - January 16, 2021
The phase 3 clinical trial of Sputnik V will be conducted on 1,500 subjects as part of the randomized, double blind, parallel group placebo controlled study in India.
Thermo Fisher completes acquisition of Henogen
By IPP Bureau - January 16, 2021
Novasep's viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally," said Michel Lagarde, executive vice president, Thermo Fisher.
Bayer gearing up for 2021-2030 decade
By IPP Bureau - January 16, 2021
Promising drug pipeline, focus on gene therapy and innovative digital health solutions will remain the key pillars of Bayer’s pharmaceutical business
Vaishali Pharma bags order worth Rs. 32 Cr
By IPP Bureau - January 14, 2021
The company is expecting tremendous growth and a better quarterly performance
Commercial disinfectants equally as effective against new COVID strains: CBC
By IPP Bureau - January 13, 2021
Viruses evolve into new strains when there is a change to their genetic composition.
